Skip to main content
Premium Trial:

Request an Annual Quote

BioGenex PD1 and PD-L1 Monoclonal Antibodies

BioGenex has launched monoclonal antibodies for the detection of immune checkpoint proteins, PD1 and PD-L1, by immunohistochemistry. The antibodies can be used to determine the expression status of target proteins in metastatic non-small cell lung cancer in formalin fixed paraffin embedded tissues. The antibodies have been validated for use in manual assays or with BioGenex automated staining systems, the company said.